Quantcast

ChromaDex to Present at the European Stevia Association (EUSTAS) Fourth International Stevia Symposium

June 24, 2010

IRVINE, Calif., June 24 /PRNewswire-FirstCall/ — ChromaDex Corporation (OTC Bulletin Board: CDXC), a world leader in phytochemical reference standards and contract testing services, announced that Frank Jaksch, president and co-founder, will be presenting on stevia testing and quality control at the European Stevia Association (EUSTAS) Fourth International Stevia Symposium on Tuesday, June 29 at 2 p.m. CET at the College Maria-Theresia in Leuven, Belgium.

By the end of 2011, it’s estimated that the stevia market could exceed $2 billion. At that rate of growth, verifying quality in both stevia based ingredients, as well as finished products, present a huge challenge to in-house and contract analytical laboratories. The presentation, entitled “Stevia Analytical Testing: Why the Industry Needs a Proficiency Program,” will discuss the stevia market, the underlying challenges for quality control and the complicated analytical testing process for this emerging ingredient.

“All stevia materials are not created equal, and the primary differences lie in the analytical data and documentation,” said Frank Jaksch of ChromaDex. “The problem with current analytical methods is that it is relatively easy to manipulate results, which drives a critical need for quality assurance in today’s stevia market. A well designed program should be able to solve many of the problems associated with differences in analytical methods.”

In November 2008, ChromaDex partnered with Cargill to supply global analytical reference standards and research materials for the individual sweet components of stevia, providing the ability for food and beverage companies to validate safety and quality of stevia for use in consumer products. Previously, there were no accepted standards for food and beverage companies to evaluate stevia-based products.

About EUSTUS

EUSTUS is a nonprofit organization founded in 2006 that aims to promote and coordinate research for stevia and related compounds to show that the ingredient is safe for human consumption. For more information, visit http://www.eustas.org/.

About ChromaDex

ChromaDex is a leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property. ChromaDex is committed to sustainable “green chemistry” and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the novel ingredients, analytical tools and services to meet product regulatory, quality, efficacy and safety standards. Among other things, the Company is currently focusing on clinical studies and the commercialization of its new product, pTeroPure(TM) pterostilbene (www.pteropure.com) as a result of its exclusive worldwide patent rights for pterostilbene. For more information, visit www.chromadex.com or follow ChromaDex on Twitter @ChromaDex.

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to: the ability to market, produce and sell the referenced ingredients; risks relating to product and customer demand, market acceptance of our products; the effect of economic conditions both nationally and internationally; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.


    Investor Inquiries
    Liviakis Financial Communications, Inc.
    John M. Liviakis, President
    415-389-4670
    John@Liviakis.com

    ChromaDex Contact
    Jenny Robles
    Administrative Assistant to the CEO
    10005 Muirlands Blvd, Suite G, Irvine, CA 92618
    949-419-0288
    jennyr@chromadex.com

    Media Contact
    Megan Lavine
    Canale Communications
    3033 5th Ave., Suite 400, San Diego, CA 92103
    619-849-5388
    megan@canalecomm.com

SOURCE ChromaDex Corporation


Source: newswire



comments powered by Disqus